DPP4 and COVID-19: While in vitro/in vivo evidence of utilization of DPP4 by SARS-CoV-2 remains lacking, clinical studies using DPP4 inhibitors have shown a reduction in respiratory complications, a decrease in mortality, and complications in COVID-19 patients [108,109].